# Effect of Glutamine Enriched Nutrition Support on Surgical Patients with Gastrointestinal Tumor: A Meta-Analysis of Randomized Controlled Trials

Kai Kang<sup>1</sup>, Xiao-Liang Shu<sup>1</sup>, Yong-Sheng Zhang<sup>2</sup>, Xian-Li Liu<sup>1</sup>, Jian Zhao<sup>1</sup>

<sup>1</sup>Department of Nutrition, East Hospital, Tong Ji University School of Medicine, Shanghai 200120, China <sup>2</sup>Department of Nutrition, First Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi 530027, China

### Abstract

**Background:** Associations between glutamine (Gln) enriched nutrition support and surgical patients with gastrointestinal (GI) tumor remain controversy. The purpose of this meta-analysis was to assess the effect of Gln enriched nutrition support on surgical patients with GI tumor in term of relevant biochemical indices, immune indices, and clinical outcomes.

**Methods:** Six databases were systematically searched to find eligible randomized controlled trials (RCTs) from 1966 to May 2014. When estimated the analysis indexes, the relative risk (RR) was used as the effect size of the categorical variable, while the weighted mean difference (MD) was used as the effect size of a continuous variable. Meta-analysis was conducted with Rev Man 5.2.

**Results:** Thirteen RCTs, involving 1034 patients, were included in the meta-analysis. The analysis showed that Gln enriched nutrition support was more effective in increasing serum albumin (MD: 0.10; 95% confidence interval [CI]: 0.02-0.18; P < 0.05), serum prealbumin (MD: 1.98; 95% CI: 1.40–2.55; P < 0.05) and serum transferring (MD: 0.35; 95% CI: 0.12–0.57; P < 0.05), concentration of IgG (MD: 1.26; 95% CI: 0.90–1.63; P < 0.05), IgM (MD: 0.18; 95% CI: 0.11–0.25; P < 0.05), IgA (MD: 0.22; 95% CI: 0.10–0.33; P < 0.05), CD3<sup>+</sup> (MD: 3.71; 95% CI: 2.57–4.85; P < 0.05) and CD4/CD8 ratio (MD: 0.27; 95% CI: 0.12–0.42; P < 0.05). Meanwhile, it was more significant in decreasing the incidence of infectious complications (RR: 0.67; 95% CI: 0.50–0.90; P < 0.05) and shortening the length of hospital stay (MD: -1.72; 95% CI: -3.31--0.13; P < 0.05).

**Conclusions:** Glutamine enriched nutrition support was superior in improving immune function, reducing the incidence of infectious complications and shortening the length of hospital stay, playing an important role in the rehabilitation of surgical GI cancer patients.

Key words: Gastrointestinal Tumor; Glutamine; Immune; Meta-analysis; Postoperation

### INTRODUCTION

Glutamine (Gln) is the most abundant naturally occurring, nonessential amino acid in the human body and one of the few amino acids that can directly cross the blood-brain barrier.<sup>[1]</sup> It is a major energy source of the cells of intestines, activated immune cells and many cancer cells with an average serum concentration of 0.6–0.9 mmol/L.<sup>[2-4]</sup> Normally, animals and humans would be rarely lack of Gln, but the serum concentration of Gln decreases significantly in the tumor-bearing state and severe traumatic stress condition, then Gln supplements become essential to meet the body's needs.<sup>[5]</sup> A series of *in vivo* studies showed that Gln could effectively improve the nutritional status, promote the body's immune function and to some extent, inhibit tumor growth.

Access this article online								
Quick Response Code:	Website: www.cmj.org							
	<b>DOI:</b> 10.4103/0366-6999.149219							

Austgen et al.<sup>[6]</sup> found that Gln-enriched total parenteral nutrition (TPN) did not stimulate tumor growth or tumor Gln metabolism. Kew et al.<sup>[7]</sup> proved that increasing the oral availability of Gln could promote the T-cell-mediated immune response. Yoshida et al.[8] demonstrated that Gln supplementation could attenuate loss of protein in the muscle in tumor-bearing animals, and protect immune and gut-barrier function during the radiochemotherapy in patients with advanced cancer. However, some results of vitro tests were on the contrary. Eagle and Piez<sup>[9]</sup> proved there was a significantly growth and proliferation of Hela cells with the addition of Gln in culture media. With studies on six different human solid tumor cell lines, Wasa et al.[10] discovered that some cancers may be better suited to survive and proliferation in a low Gln environment than others. Therefore, associations between Gln enriched nutrition support and surgical patients with gastrointestinal (GI)

Address for correspondence: Prof. Xiao-Liang Shu, Department of Nutrition, East Hospital, Tong Ji University School of Medicine, No.150, Jimo Road, Pudong District, Shanghai 200120, China E-Mail: shuxiaoliang@vip.sina.com tumor remain controversy. The aim of this study was to review systematically and meta-analysis all randomized controlled trials (RCTs) thus investigating the effects of Gln enriched nutrition support on surgical patients with GI tumor published from 1966 to May 2014, to provide further evidence for rational clinical application of Gln.

# Methods

# **Study selection**

We systematically searched 6 databases (PubMed [http:// www.pubmed.com], EMBASE [http://www.embase.com], Web of Science [http://apps.webofknowledge.com], The Cochrane Library [http://www.thecochranelibrary.com]), China National Knowledge Infrastructure (CNKI, http:// www.cnki.net/), VIP (http://www.cqvip.com/) for all RCTs investigating the effects of Gln enriched nutrition support ("nutritional support," "nutrition supplement," "enteral nutrition," "parenteral nutrition (PN)," "TPN" and their variants) on postoperative ("surgery," "operative," "operation," "preoperative," "preoperation," "perioperative," "perioperation," "postoperative," "postoperation," "resection," "gastrectomy," "enterectomy" and their variants) patients of GI tumor ("GI," "upper GI," "lower GI," "digestive tract," "gastric," "colon," "colorectal," "cancer," "neoplasms" and their variants) published from 1966 to May 2014. References from the extracted articles and reviews were also consulted to complete the data bank. When multiple articles for a single study were present, we used the latest publication and supplemented it, if necessary, with data from the most complete or updated publication.

Studies were included if (i) they were the RCTs with parallel controlled design; (ii) the objects of study were surgical patients with GI tumor; (iii) the supplementation of GIn was the only difference between the treatment group and the control group; (iv) specific outcomes were mentioned, including relevant biochemical indices (serum total protein, serum albumin, serum prealbumin and serum transferrin), immune indices (concentration of IgG, IgM, IgA, CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, CD4/CD8 ratio and tumor necrosis factor alpha [TNF- $\alpha$ ]) and clinical outcomes (infectious complication, noninfectious complication [Table 1] and length of hospital stay); and (v) data related to supplementation of were available. And we excluded studies if (i) they were not randomized designs; (ii) they did not report an adequate statistical analysis; and (iii) reviews or case reports.

## **Data extraction**

From each study, we extracted information on first author, publication year, country of origin, sample size, age, sex, type of diseases, average study follow-up time, number of subjects, type of nutrition support, duration of Gln enriched nutrition support, daily dose of Gln, disease outcome, method of outcome ascertainment, unit of measurement, and corresponding 95% confidence interval (CI), standard deviation (SD), or exact P value. Because differences in study populations and design might cause variations in

# Table 1: Classification of complications in the included trials

Infectious complications	Noninfectious complications
Pneumonia	Anastomotic leak
Abdominal abscess	Wound dehiscence
Fasciitis	Gastrointestinal bleeding
Bacteremia	Gastrointestinal perforation, obstruction and ischemia
Septic shock	Pancreatitis
Septic coagulopathy	Myocardial infarction
Wound infections	Cardiogenic shock
Urinary tract infections	Cardiopulmonary arrest
Central venous catheter infectious	Stroke
	Pulmonary embolus
	Hemoperitoneum
	Pulmonary failure
	Renal failure
	Pleural effusion
	Hepatic dysfunction

results, study-quality score was made by methodology quality assessment.<sup>[11]</sup> A study-quality score was calculated for each of included traits ranged from 0 to 5. Studies were categorized into those with a high study quality score (3–5 points) and those with a low study-quality score (1–2 points), and no RCTs (0 point).

## **Data analysis**

Data pooling was performed with the use of classical meta-analytic methodology, using the RevMan 5.2 Copenhagen: The Nordie Cochrane Centre, The Cochrane Collaboration, 2012 http://ims.cochrane.org/revman/). P < 0.05 was considered statistically significant. Data were extracted from the text, tables and figures of the original published papers. To include data from as many trials as possible, missing SD data for one trial were imputed from SD data from all other trials using the same measure.<sup>[12]</sup> When estimated the analysis indexes, the relative risk (RR) was used as the effect size of the categorical variable, while the weighted mean difference (MD) was used as the effect size of a continuous variable. 95% CIs were calculated for each investigation and for each outcome variable. Before calculating the standardized mean effect for all trials, statistical heterogeneity test was evaluated by using the  $I^2$ statistic ( $\alpha = 0.05$ ), which assessed the appropriateness of pooling the individual study results. The  $I^2$  value provided an estimate of the amount of variance across studies because of heterogeneity rather than chance.<sup>[13]</sup> And  $I^2$  values of 25%, 50%, and 75% corresponded to low, moderate, and high levels of heterogeneity, respectively. If  $P \ge 0.05$ , the heterogeneity was not substantial, there was low heterogeneity between the trials. Thus, fixed-effects models were used, with Mantel-Haenszel method weighting for combined statistics. If P < 0.05, however, the heterogeneity was considered substantial, there was high heterogeneity between the trials. In this situation, subgroup analysis would be performed. If subgroup analysis could not remove the heterogeneity,

combined results were conducted with random-effects models, which were inversed variance weighting or DerSimonian-Laird method based on fixed-effects models. Moreover, a *priori* potential sources of heterogeneity were publication bias. Possible publication bias was investigated by drawing a funnel plot to look for funnel plot asymmetry and meta-regression based on study size.<sup>[14]</sup>

# RESULTS

#### **Characteristics of the studies**

The initial search yielded 776 potentially relevant references. After removing duplicates, reviews, animal trials and papers that were less related according to the titles and abstracts, there were 59 studies left. Then reading the full text of these studies and excluding the studies that were less related, 13 trials<sup>[15-27]</sup> met the inclusion criteria and were selected as appropriate for inclusion in this meta-analysis [Figure 1]. The included trials were published between 1966 to May 2014. The sample size varied from 11 to 428, reaching a total of 1034. The characteristics of the selected trials are presented in Table 2.

#### **Relevant biochemical indices**

#### Serum total protein

Totally 122 participants from three studies<sup>[18,24,27]</sup> were enrolled to evaluate the change of serum total protein (g/L), the heterogeneity of which ( $I^2 = 58\%$ ; P = 0.09; Chi-square = 4.81) was acceptable, so the fixed-effects model was used. The analysis showed that there was no statistically significant difference between the Gln and control group (MD: 0.86; 95% CI: -0.28–1.99; P > 0.05), from which we could draw the conclusion that Gln enriched nutrition support had no more difference in changing the serum total protein than control group [Figure 2a].

#### Serum albumin

A total of 356 participants from six studies<sup>[18,20,21,23,26,27]</sup> were enrolled in the serum albumin (g/dl) analysis, the heterogeneity

of which ( $I^2 = 51\%$ ; P = 0.07; Chi-square = 10.15) was acceptable, so the fixed-effects model was used. There was statistically significant difference between Gln and control group (MD: 0.10; 95% CI: 0.02–0.18; P < 0.05) [Figure 2b].

#### Serum prealbumin

Six studies<sup>[17,18,21,23,24,26]</sup> with 324 subjects mentioned the data of serum prealbumin (mg/dl). The fixed-effects model was used, for the heterogeneity was acceptable ( $I^2 = 38\%$ ; P = 0.15; Chi-square = 8.06). The analysis suggested that Gln enriched nutrition support performed more effective in increasing serum prealbumin (MD: 1.98; 95% CI: 1.40–2.55; P < 0.05) than control [Figure 2c].

#### Serum transferring

There were five studies<sup>[17,18,23,24,26]</sup> with 274 subjects that mentioned the change of serum transferring (g/L) between the Gln and control group, but the heterogeneity among them was significant ( $I^2 = 76\%$ ; P < 0.05; Chi-square = 16.45). Thus, we performed a subgroup analysis according to



Figure 1: Flow diagram of trial selection process resulting from systematic search.

Table 2: Chara	Table 2: Unaracteristics of the trials included in the meta-analysis, by year of publication*													
Author	Year	Country	Type of diseases	Age (years)	Sex (male/ female)	Number of subjects (treatment/ control)	Type of nutrition support	Daily dose of glutamine	Duration (days)	Design	Study- quality score			
Aosasa et al.[15]	1999	Japan	Colorectal cancer	$63.8 \pm 10.7$	7/4	11 (6/5)	TPN	30 g/kg	≥5	R, PC	3			
Dai et al.[17]	2001	China	Gastrointestinal cancer	61.2	11/9	20 (10/10)	TPN	20 g/kg	8	R, PC	3			
Erdem et al.[18]	2002	Turkey	Gastrointestinal cancer	26 - 70	16/16	32 (16/16)	EN	0.2 g/kg	17	R, PC	3			
Huang et al.[20]	2002	China	Colorectal carcinoma	41 - 70	16/6	22 (11/11)	PN	0.2 g/kg	6	R, PC	3			
Weng et al.[24]	2006	China	Gastric cancer	$67.8\pm4.1$	23/7	30 (15/15)	PN	0.2 g/kg	7	R, PC	3			
Xia et al. <sup>[25]</sup>	2006	China	Gastrointestinal cancer	$60.4 \pm 11.1$	21/19	40 (20/20)	TPN	0.3 g/kg	10	R, PC	3			
Oguz et al.[22]	2007	Turkey	Colorectal cancer	$57 \pm 17$	71/38	109 (57/52)	EN	1 g/kg	5 - 8	R, PC	3			
Wang and Che <sup>[23]</sup>	2007	China	Gastrointestinal cancer	35 - 62	32/28	60 (30/30)	PN	0.4 g/kg	7	R, PC	3			
Yang et al. <sup>[26]</sup>	2008	China	Digestive tract cancer	$63 \pm 10$	87/45	132 (70/62)	EN	0.5 g/kg	7	R, PC	3			
Gianotti et al. <sup>[19]</sup>	2009	Italy	Major gastrointestinal cancer	>18	260/168	428 (212/216)	PN	0.4 g/kg	≥6	R, PC	3			
Cui et al.[16]	2011	China	Colon cancer	35 - 75	23/17	40 (20/20)	PN	0.5 g/kg	2	R, PC	3			
Lu et al.[21]	2011	China	Gastrointestinal cancer	$66.8 \pm 14.9$	34/16	50 (25/25)	TPN	0.3 g/kg	7	R, PC	3			
Zhao et al.[27]	2012	China	Gastric cancer	$58.2 \pm 12.5$	35/25	60 (30/30)	PN	0.4 g/kg	10	R, B, PC	4			
*EN: Enteral nut	rition.	PN· Paren	teral nutrition: TPN: Tot	al parenteral	nutrition.	B. Blind: PC · P	arallel-cont	rolled R · R	ndomized					

'EN: Enteral nutrition; PN: Parenteral nutrition; TPN: Total parenteral nutrition; B: Blind; PC: Parallel-controlled; R: Randomized

Chinese Medical Journal | January 20, 2015 | Volume 128 | Issue 2

different countries and regions.  $I^2$  between subgroups was 0% (P = 0.36; Chi-square = 0.85), but the total heterogeneity was still large. In this case, we used a random-effects model to analyze the data. There was significantly increase of serum transferring in Gln group (MD: 0.35; 95% CI: 0.12–0.57; P < 0.05) [Figure 2d]. Moreover, the symmetry funnel plot suggested scarcely any publication bias existed between studies mentioned change of serum transferring [Figure 3].

#### **Relevant immune indices**

#### Concentration of IgG, IgM and IgA

There were six studies<sup>[17,20,23,24,26,27]</sup> with 324 subjects that mentioned the compare of relevant immune globulin between two groups. The fixed-effects model was used, for the heterogeneity of three variables was acceptable [Figure 4a-c]. The analysis suggested that Gln could improving the immune function with higher concentration of IgG (MD: 1.26; 95% CI: 0.90–1.63; P < 0.05), IgM (MD: 0.18; 95% CI: 0.11–0.25; P < 0.05) and IgA (MD: 0.22; 95% CI: 0.10–0.33; P < 0.05).

#### Change of CD3+, CD4+, CD8+ T-cell and CD4/CD8 ratio

There are five studies<sup>[23-27]</sup> with 322 subjects that mentioned the change of CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup> T-cell and CD4/CD8 ratio. The heterogeneity of CD3<sup>+</sup> and CD8<sup>+</sup> T-cell was acceptable, so the fixed-effects model was used [Figure 5a and c].



**Figure 2:** Forest plot of relevant biochemical indices between Glutamine and control group. (a) Change of serum total protein between glutamine and control group: Fixed-effects model. (b) Change of serum albumin between glutamine and control group: Fixed-effects model. (c) Change of serum prealbumin between glutamine and control group: Fixed-effects model. (d) Change of serum transferrin between glutamine and control group: Subgroup analysis with random-effects model. While the heterogeneity among CD4<sup>+</sup> T-cell and CD4/CD8 ratio was significant, so the random-effects model was used [Figure 5b and d]. Analysis suggested Gln enriched nutrition support could effectively increase postoperative CD3<sup>+</sup> T-cell (MD: 3.71; 95% CI: 2.57–4.85; P < 0.05) and CD4/CD8 ratio (MD: 0.27; 95% CI: 0.12–0.42; P < 0.05) of GI cancer patients. But changes between CD4<sup>+</sup> (MD: 4.11; 95% CI: -0.82–9.04; P > 0.05) and CD8<sup>+</sup> (MD: -0.37; 95% CI: -1.12–0.38; P > 0.05) T-cell were not statistically significant.

#### Concentration of tumor necrosis factor alpha

In the analysis for concentration of TNF- $\alpha$  (pg/ml), 101 patients in three studies<sup>[15,16,21]</sup> were extracted. The heterogeneity among them was significant ( $I^2 = 89\%$ ; P < 0.05; Chi-square = 17.77), thus we used a random-effects model to analyze the data. The change of concentration of TNF- $\alpha$  was not statistically significant (MD: -7.34; 95% CI: -18.15-3.47; P > 0.05) [Figure 6].

#### **Relevant clinical outcomes**

#### Infectious complications

Eight studies,<sup>[19-22,24-27]</sup> 872 subjects included, evaluated the effect of Gln enriched nutrition support on infectious complications, and the analysis showed a trend towards a reduction of postoperative infectious complications (RR: 0.67; 95% CI: 0.50–0.90; P < 0.05) in GI cancer patients [Figure 7a]. Moreover, the fixed-effects model was used with acceptable heterogeneity ( $I^2 = 49\%$ ; P = 0.06; Chi-square = 13.61).

#### **Noninfectious complications**

From three studies<sup>[19,20,22]</sup> 559 participants were enrolled to evaluate the incidence of noninfectious complications, the heterogeneity of which ( $I^2 = 17\%$ ; P = 0.28; Chi-square = 10.87) was acceptable, so the fixed-effects model was used. However, there was no statistically significant difference between the two groups (RR: 0.80; 95% CI: 0.53–1.21; P > 0.05), from which we could draw



**Figure 3:** Funnel plot of studies mentioned change of relevant biochemical indices between glutamine and control group. Dotted lines are pseudo 95% confidence intervals. The asymmetry funnel plot suggested possible publication bias existed, which was associated with the significant heterogeneity of studies mentioned change of serum transferrin.

Study of Subscroup         Mean         SD         Total         Mean         SD		Gin Control Mean Difference						Mean Difference			
Dal et al 2001 Plang et al 2002 Plang et al 2002 Plang et al 2002 Plang et al 2002 Plang et al 2004 Plang et al 2	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV. Fixed, 95% CI	
Huang etal 2002       14.7       2.1       11       6.6 %       1.50 [0.07, 2.83]         Weng etal 2005       14.13       1.09       15       1.25       2.28       1.41 [0.75, 2.06]         Yang etal 2006       15.9       9.70       1.3.6       6.22       2.29       1.41 [0.75, 2.06]         Yang etal 2006       15.9       9.70       1.5.6       6.2       4.90       2.50 [0.66, 4.34]         Zhan et al 2012       1.23       4.36       30       1.01       6.09       30       1.9%       1.28 [0.30, 1.63]         Intercogeneity: Cht" = 4.10, df = 50 (* 0.64); ff = 0%       Total (95% Cl)       166       158       100.0%       1.28 [0.30, 0.24]         Huang etal 2002       1.3       0.8       10       1.0       10       10       10.2       102       10.27 (35% 0.10 (-0.40, 0.24)         Huang etal 2002       1.3       0.8       11       1.6       0.41       1.16       0.21 (0.27 % 0.10 (-0.40, 0.24)         Huang etal 2002       1.3       0.8       70       2.03 (0.10 (0.3), 0.3)       0.38       0.43       0.39       0.41 (0.14, 0.23)       0.42 (0.16, 0.30)       1.35       1.35       1.36.0       0.41 (0.14, 0.23)       1	Dai et al 2001	8.59	0.46	10	7.33	0.84	10	38.3%	1.26 [0.67, 1.85]		
Wang et al 2007       9.6       1.37       30       8.09       1.18       30       32.2%       1.14       10,76,2.06]         Wang et al 2006       1.6.3       9.19       15       15.32       15       17,0%       0.01       10,35,1.50]         Yang et al 2006       1.6.3       30       11.01       6.09       30       19%       1.28(0.50,4.34)         Zhan et al 2012       12.3       4.36       30       11.01       6.09       30       19%       1.28(0.50,4.34)         Total (95% C1)       1.66       158       100.0%       1.28(0.50,1.63)       1.26(0.50,1.63)         Heterogeneity: Chi*=4.10, dr= 5 (P = 0.54); F = 0%       1.26(0.50,0.163)       1.26(0.50,0.21)       Favours (Centrol       Favours (Gentrol       Mean Difference         Study or Subgroup       Mean       SD       Total       Mean       5D       Total       Mean 2014 (1.4,0.34)       1.1       1.1       1.42       0.30,0.73       Wang et al 2002       1.80       0.95       6.1       1.33       10.0.50       0.48 (0.14,0.24)       1.43       1.43       1.43       1.43       1.43       1.43       1.44       1.44       1.24       1.43       1.44       1.26       0.44 (0.14,0.24)       1.45       1.43	Huang et al 2002	14.7	2.1	11	13.2	1.2	11	6.6%	1.50 [0.07, 2.93]		
Weng et al 2006       14.13       1.09       15       15.25       13.62       1.36       1.26       1.26       1.26       1.36       1.26       1.26       1.26       1.36       1.2	Wang et al 2007	9.6	1.37	30	8.09	1.18	30	32.2%	1.41 [0.76, 2.06]		
Yang et al 2006       15.9       4.9       70       13.4       5.6       6.2       4.9%       2.50       0.66, 4.34         Total (95% CI)       12.6       30       11.01       6.00       30       12.8       10.9%       1.28       1.38, 397         Total (95% CI)       166       158       100.0%       1.26       0.9%       1.28       0.9%       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0.16       0	Weng et al 2006	14.13	1.09	15	13.52	1.38	15	17.0%	0.61 [-0.28, 1.50]	+	
Zhao et al 2012       1 2.3       4.36       30       11.01       6.09       30       1.9%       1.28 [1.39, 3.97]         Total (95% CI)       Mean SID Total Weight M. Pixed, 95% CI         Date et al 2001       1.1       0.1       0.2       10       2.1       30       0.21       Mean SID Total Weight M. Pixed, 95% CI         Date et al 2001       1.3       0.8       1.6       0.4       11       1.9%       0.20 (0.33, 0.73)         Yang et al 2002       1.3       0.8       70       2.0       9.2       6.2%       0.01 (0.40, 0.24)         Total (95% CI)       1.51       143       100.0%       0.01 (0.10, 0.3)       0.1       0.5       Total (0.14, 0.25)         Table et al 2001       1.7       0.1       1.6       0.4       11       1.9%       0.21 (0.33, 0.73)         Yang et al 2002       1.9       0.8       70       2.0       9.2       0.25%       0.24 (0.14, 0.23)       0.25         Total (95% CI)       151       143       100.0%       0.16 (0.14, 0.25)       Mean Difference       Mean Difference       Man Difference       Man Di	Yang et al 2008	15.9	4.9	70	13.4	5.8	62	4.0%	2.50 [0.66, 4.34]		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Zhao et al 2012	12.3	4.36	30	11.01	6.09	30	1.9%	1.29 [-1.39, 3.97]		
Control     Mean Difference       Control     Mean Difference       Study or Subgroup     Mean Difference       Mung etal 2001     1.0       1.0     1.0 <td< td=""><td>Total (95% CI)</td><td></td><td></td><td>166</td><td></td><td></td><td>159</td><td>100.0%</td><td>1 26 [0 00 1 63]</td><td>•</td></td<>	Total (95% CI)			166			159	100.0%	1 26 [0 00 1 63]	•	
Test for overall effect Z = 6.3 (P ≤ 0.001) Test for overall effect Z = 6.3 (P ≤ 0.001) Gin Control Mean SD Total Mean SD Total Weildt M, Fixed, 95% CI Huang et al 2002 1.8 0.8 11 1.6 0.4 11 1.9% 0.20 (D.33, 0.73) Yang et al 2002 1.8 0.8 11 1.6 0.4 10 2.10 2.7% 0.016 (D.04, 0.24) Huang et al 2002 1.8 0.8 11 1.6 0.4 11 1.9% 0.20 (D.33, 0.73) Yang et al 2002 1.8 0.8 70 2 0.9 62 6.2% 0.10 (D.04, 0.24) Heterogeneity, ChF = 5.3, dir 4 (P = 0.17), F = 37%. Test for overall effect Z = 4.80 (P < 0.0001) Gin Control Mean SD Total Weilth M, Fixed, 95% CI Heterogeneity, ChF = 6.39, dir 4 (P = 0.17), F = 37%. Test for overall effect Z = 4.80 (P < 0.0001) Gin Control Mean SD Total Weilth M, Fixed, 95% CI Heterogeneity, ChF = 6.39, dir 4 (P = 0.17), F = 37%. Test for overall effect Z = 4.80 (P < 0.0001) Gin Control Mean SD Total Weilth M, Fixed, 95% CI Dat et al 2002 1.7 1.1 0.1 10 1.6 0.4 10 2.10% 0.10 (D.01, 0.26) Hang et al 2002 2.3 0.5 11 1.8 0.7 11 5.3% 0.30 (D.01, 0.1) Wang at al 2007 2.85 0.39 30 2.61 0.37 30 37.1% 0.24 (105, 0.48) Vang et al 2002 2.7 1.1 1.7 0.23 0.9 62 2.11.8% 0.010 (D.0.0, 0.60) Yang et al 2002 2.7 1.1 1.7 0.23 0.9 67 30 9.60 0.47 (100, 0.85) Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.33] Heterogeneity, ChF = 7.37, dir 5 (P = 0.109, F = 32%. Test for overall effect Z = 3.60 (P = 0.0005)	Hotorogonoity: Chill -	4.10.46	- 5 /P	- 0.64		<i>v</i> .	150	100.070	1.20 [0.30, 1.03]		
Test on other an effect 1 = 0.14 (* 0.00001)       Favours (Control       Mean Difference       N. Freed, 95% CI       Date at all 2001       1.1     0.1     1.0     1.0     2.7.5%     0.10-0.04, 0.24       Phane at al 2001       Total Mean       Diate at al 2001       1.1       Other Mean Difference       N. Freed, 95% CI       Phane at al 2001       Total Mean       Statute or subscream       Mean Difference       N. Freed, 95% CI       Total Veight M. Freed, 95% CI       Diate al 2001       Total Veight M. Freed, 95% CI       Diate al 2001       Total Veight M. Freed, 95% CI       Diate al 2001       Total Veight M. Freed, 95% CI       Date at 2000 <td< td=""><td>Tact for overall effect:</td><td>7-674</td><td>- 0 (r 1 / P ~ 1</td><td>0.04</td><td>), i = 03 IN</td><td>ro -</td><td></td><td></td><td></td><td>-2 -1 0 1 2</td></td<>	Tact for overall effect:	7-674	- 0 (r 1 / P ~ 1	0.04	), i = 03 IN	ro -				-2 -1 0 1 2	
Gin         Control         Mean Difference         Mean Difference           Dal et al 2001         1.1         0.1         0.2         10.2	rescior overall ellect.	2 = 0.74	.(- < )	0.000	·					Favours [Control] Favours [Gin]	
Study or Subgroup         Mean         SD         Total         Mean         SD			Gin		c	ontrol			Mean Difference	Mean Difference	
Del et al 2001 1.1 0.1 10 1 0.2 10 27.5% 0.1016-034, 0.24 Privang et al 2007 1.6 0.4 11 1.6 0.4 11 1.4 5% 0.204-0.33, 0.73] Wang et al 2007 1.6 0.14 20 1.4 2, 0.23 30 67.0% 0.24 [0.14, 0.34] Yang et al 2008 1.9 0.8 70 2.0 9 62 6.2% 0.10 [0.39, 0.19] Zhane et al 2012 1.17 0.43 30 0.95 0.61 30 7.4% 0.22 [0.505, 0.49] Total (95% CI) 151 143 100.0% 0.18 [0.11, 0.25] Heterogenetic: Ch <sup>2</sup> = 6.39, df = 4 (P = 0.17), P = 37%. Test for overall effect Z = 4.00 P < 0.0001) Total (95% CI) 1.0 10 1.6 0.4 10 2.10% 0.1016 0.24] Huang et al 2002 2.3 0.5 11 1.8 0.7 11 5.3% 0.36 [P-01, 10.3] Wang et al 2002 2.3 0.5 11 1.8 0.7 11 5.3% 0.36 [P-01, 10.3] Wang et al 2002 2.4 0.42 15 2.37 0.42 15 15.2% 0.30 [P-00, 0.64] Wang et al 2006 2.87 0.42 15 2.37 0.42 15 15.2% 0.30 [P-00, 0.64] Wang et al 2006 2.87 0.42 15 2.37 0.42 15 15.2% 0.30 [P-00, 0.65] Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.19), P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.09), P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.09), P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.09), P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.09), P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.00); P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.09), P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.00); P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.00); P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.00); P = 32%. Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.3] Heterogenetic: Ch <sup>2</sup> = 7.37, df = 5 (P = 0.00); P = 32%. Total (95% CI) 166 158 100.	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Fixed, 95% CI	IV. Fixed. 95% CI	
Fusing et al 2002     1.8     0.8     1.1     1.6     0.4     1.1     1.9     0.20 [D 33, D 73]       Yang et al 2007     1.66     0.8     7.0     2.0     9.6     2.6     0.5%     0.24 [D 16, 0.34]       Yang et al 2008     1.9     0.8     70     2.0     9.6     2.2     6.2%     0.10 [D 33, 0.19]       Zhae et al 2012     1.17     0.43     30     0.95     0.61     30     7.4%     0.22 [D .05, 0.49]       Total (95% C)     151     143     100.0%     0.18 [0.11, 0.25]     -1     -0.5     0.5       Favours [Control     Mean Difference     Mean Difference     Mean Difference     Mean Difference     Mean Difference       Study of Subgroup     1.7     0.1     10     1.6     0.41     0.21 (D .0.4)     0.41       Hear get al 2002     2.3     0.3     3.0     7.3%     0.36     0.04 (D .0.5, 0.4)       Dai et al 2001     1.7     0.1     1.6     0.7     1.6     0.44 (D .0.5, 0.4)       Wang at 2002     2.8     0.39     3.0     7.4%     0.35     0.60 (D .0.1, 0.1)       Wang at 2002     2.8     0.21     0.7     1.5     0.7     0.6%     0.47 (D .0.6, 0.4)       Yang et al 2002     2.4	Dai et al 2001	1.1	0.1	10	1	0.2	10	27.5%	0.10 (-0.04, 0.24)		
Wang of al 2007       1.66       0.14       30       1.42       0.23       30       67.0%       0.24 (D.14, 0.24)         Yang of al 2008       1.9       0.8       70       2.9       62.6       62.6       0.10       0.30       0.11         Zhao et al 2012       1.17       0.43       30       0.95       0.61       30       7.4%       0.22 (0.05, 0.49)         Total (95% CI)       151       143       100.0%       0.18 (0.11, 0.25)       1       -0.5       0.5         Test for overall effect Z=4.800 P < 0.0001)	Huang et al 2002	1.8	0.8	11	1.6	0.4	11	1.9%	0.20 (-0.33, 0.73)		
Yang #12008         1.8         0.8         70         2         0.9         8.2         6.2%         6.10         6.10         7.3         0.11         7.3         0.11         7.3         0.11         7.3         0.11         7.3         0.11         7.3         0.11         7.3         0.11         7.3         0.11         7.3         0.11         7.3         0.11         7.3         0.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11         1.11	Wang et al 2007	1.66	0.14	30	1.42	0.23	30	57.0%	0.24 (0.14, 0.34)		
Zhao et al 2012         1.17         0.43         30         0.95         0.61         30         7.4%         0.22 [-0.05, 0.46]           Total (95% Ct)         151         143         100.9%         0.18 [0.11, 0.25]         1         -0.5         0         0.5           Test for overall effect Z= 4.50 (P = 0.00001)         Test for overall effect Z= 4.50 (P = 0.00001)         Mean Difference         Mean Di	Yang et al 2008	1.9	0.8	70	2	0.9	62	6.2%	-0.101-0.39.0.191		
Control (95% C)         151         143         100.0%         0.48 [0.11, 0.25]           Heterogeneity: Chiff = 6.39, df = 4 (P = 0.17), IF = 37%.         Test for overall effect Z = 4.80 (P < 0.0000)	Zhao et al 2012	1.17	0.43	30	0.95	0.61	30	7.4%	0.22 (-0.05, 0.49)	<u> </u>	
Gin         Control         Mean Difference											
Heterogeneity: Chi <sup>2</sup> = 5.39, df = 4 (P = 0.17), F = 37%, Test for overall effect Z = 4.80 (P < 0.0001) Control Mean Difference Study of Subgroup Mean SD Total Mean SD Total Weight M, Fixed, 95% Cl Dal et al 2001 1.7 0.1 10 1.8 0.4 10 21.0% 0.10 (2.016.0.86) Huang et al 2002 2.3 0.5 11 1.8 0.7 11 5.3% 0.26 (2.01.0.1) Wang et al 2002 2.85 0.33 30 2.61 0.37 30 37.1% 0.24 (10.56, 0.48) Wang et al 2006 2.87 0.42 15 2.97 0.42 15 1.57% 0.30 (2.00, 0.66) Yang et al 2006 2.2 0.1 1.9 0.67 30 0.96 0.47 (10.09, 0.65) Total (95% Cl) 166 150 100.0% 0.22 (0.10, 0.33) Heterogeneity: Chi <sup>2</sup> = 7.37, df = 5 (P = 0.19), F = 32%, Tast for overall effect Z = 3.00 (P = 0.005)	Total (95% CI)			151			143	100.0%	0.18 [0.11, 0.25]	•	
Test for overall effect Z = 4.80 (P < 0.00001)           Gin         Control         Favours (Control         Favours (Control <th colspa<="" td=""><td>Heterogeneity: Chi<sup>2</sup> =</td><td>6.39, df</td><td>= 4 (P</td><td>= 0.17</td><td>); <b>P</b>= 37</td><td>%</td><td></td><td></td><td></td><td>-1 -05 0 05 1</td></th>	<td>Heterogeneity: Chi<sup>2</sup> =</td> <td>6.39, df</td> <td>= 4 (P</td> <td>= 0.17</td> <td>); <b>P</b>= 37</td> <td>%</td> <td></td> <td></td> <td></td> <td>-1 -05 0 05 1</td>	Heterogeneity: Chi <sup>2</sup> =	6.39, df	= 4 (P	= 0.17	); <b>P</b> = 37	%				-1 -05 0 05 1
Gin         Control         Mean Difference         Mean Difference           Study or Subgroup         Mean         SD. Total Mean         SD. Total Weinitt         M. Fixed, 95% CI           Date at 2002         2.3         0.5         11         10         6.6         4.0         21.0%         0.140 https://doi.010/16.0.361           Huang et al 2002         2.3         0.5         11         1.6         0.4         10.2         0.0%         0.140 https://doi.010/16.0.361           Weng et al 2002         2.3         0.3         3.0         2.81         0.37         30         37.1%         0.34 (10.05, 0.45]           Weng et al 2006         2.2         1.1         170         2.3         0.9         2.2         1.1.8%         0.016 (10.40, 0.24)           Yang et al 2006         2.2         2.1         1.0         0.7         0.9 et 6.7         0.04%         0.440 (10.24, 0.24)           Zhane et al 2012         2.48         0.91         0.90.77         0.96%         0.47 (10.09, 0.65)         1.1         0.0.5           Total (95% CI)         166         158         100.0%         0.22 (0.10, 0.33)         1.1         -0.5         0.0.5           Fast for overall effect Z = 3.00 (P = 0.003)         Date 22 (0.00, 0	Test for overall effect:	Z = 4.80	) (P < I	0.0000	I)					Favours [Control] Favours [Gin]	
Gin         Control         Mean Difference         Mean Difference         Mean Difference           Study or Subgroup         Maan         SD         Total Mean         SD										d P	
Study or Subgroup         Mean         SD         Total         Weight         M. Rixed, 95% CI         M. Fixed, 95% CI           Date at 2001         1.7         1         1         6.4         10         21.0%         0.10 + 0.16         0.36           Huang ptal 2002         2.3         0.5         11         1         0.5         0.4         10         21.0%         0.10 + 0.16         0.36           Huang ptal 2002         2.3         0.5         11         1.8         0.7         0.37         0.37         0.37         0.37         0.37         0.47         0.50         0.10 + 0.50         0.43         10         15         0.47         0.05         0.47         0.05         0.47         0.05         0.47         0.06         0.40         0.21         0.42         15         15.2%         0.30         0.26         0.47         0.09         0.65         10.09         0.67         0.9         9.65         0.47         0.09         0.65         10         10.09         0.67         0.05         10         0.45         10         0.45         10         0.45         10         0.45         10         0.45         10         0.45         10         0.45         10			Gin		0	ontrol			Mean Difference	Mean Difference	
Dai et al 2001 1.7 0.1 10 1.6 0.4 10 21.0% 0.10 P.0.16, 0.36 Huang et al 2002 2.3 0.5 11 1.8 0.7 11 5.5% 0.50 F.0.01, 1.01] Wang et al 2002 2.87 0.42 15 2.37 0.42 15 15.2% 0.30 F.0.00, 0.60] Wang et al 2006 2.2 1.1 70 2.3 0.9 62 11.4% -0.010-4.40, 0.24] Zhane et al 2012 2.46 0.82 30 1.99 0.67 30 9.6% 0.47 (0.09, 0.85] Heterogeneity: ChP <sup>2</sup> = 7.37, df = 5 (P = 0.19), P = 32% Total (95% Ch) = 6(P = 0.19), P = 32% Test for overall effect Z = 3.60 (P = 0.0003)	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV. Fixed, 95% CI	
Huang et al 2002 2.3 0.5 11 1.8 0.7 11 5.3% 0.50 (P.0.1, 1.01) Wang et al 2002 2.8 0.6 11 0.37 30 371% 0.24 (D.50, 0.43) Wang et al 2006 2.87 0.42 15 2.37 0.42 15 15.2% 0.30 (P.0.0, 0.60) Yang et al 2006 2.2 1.1 7 0 2.3 0.9 62 1148% -0.1016-0.44, 0.24 (D.24) Zhao et al 2012 2.46 0.82 30 1.99 0.67 30 9.6% 0.47 (D.09, 0.85) Total (95% Ch) 166 158 100.0% 0.22 (0.10, 0.33) Heterogeneity: Chi <sup>2</sup> = 7.37, df = 5 (P = 0.19); P = 32% Test for overall effect Z = 3.00 (P = 0.003)	Dai et al 2001	1.7	0.1	10	1.6	0.4	10	21.0%	0.10 [-0.16, 0.36]	-+	
Wang di 2007       2.85       0.39       30       2.61       0.37       30       37.1%       0.24 (D.05, 0.43)         Wang di 2008       2.20       1.5       2.7       0.42       15       5.25       0.30, 10.00, 0.60]         Yang etai 2008       2.2       1.1       70       2.3       0.9       62       11.8%       -0.10 [-0.44, 0.24]         Zhao etai 2012       2.46       0.82       30       1.99       0.67       30       9.6%       0.47 (D.09, 0.65]         Total (95% Ct)       166       158       100.0%       0.22 [0.10, 0.33]       -1       -0.5       0       0.5         Test for overall effect Z= 3.60 (P = 0.109); P = 32%       52%       52%       53%       54%       0.5       Favours [Control]       Favours [Control]       Favours [Control]       Control       54%	Huang et al 2002	2.3	0.5	11	1.8	0.7	11	5.3%	0.50 [-0.01, 1.01]		
Weng et al 2006         2.87         0.42         15         2.37         0.42         15         15.2%         0.30 (P.00, 0.60)           Yang et al 2008         2.2         1.7         70         2.3         0.9         62         11.9%         -0.10 (0.44)         0.44         0.42         15         16.2%         0.30 (P.00, 0.60)         -	Wang et al 2007	2.85	0.39	30	2.61	0.37	30	37.1%	0.24 [0.05, 0.43]		
Yang et al 2008 2.2 1.1 70 2.3 0.9 62 11.8% -0.10 F.0.44, 0.241 Zhao et al 2012 2.46 0.82 30 1.99 0.67 30 9.6% 0.47 [0.09, 0.65] Total (95% CI) 166 158 100.0% 0.22 [0.10, 0.33] Heterogeneity: ChP = 7.37, df = 5 (P = 0.19), P = 32% Test for overall effect Z = 3.60 (P = 0.0003) Test for overall effect Z = 3.60 (P = 0.0003)	Weng et al 2006	2.67	0.42	15	2.37	0.42	15	15.2%	0.30 [-0.00, 0.60]		
Zhao et al 2012 2.46 0.82 30 1.99 0.67 30 9.6% 0.47 [0.09, 0.85] Total (6% Ch) 166 158 100.0% 0.22 [0.10, 0.3] Heterogeneity: Chi <sup>2</sup> = 7.37, df 5 (P = 0.19), l <sup>2</sup> = 32% Test for overall effect Z = 3.60 (P = 0.0003) Favours [Control] Favours [	Yang et al 2008	2.2	1.1	70	2.3	0.9	62	11.8%	-0.10 [-0.44, 0.24]		
Total (95% CI)         166         158         100.0%         0.22 [0.10, 0.33]           Heterogeneity: Chi <sup>2</sup> = 7.37, df = 5 (7 <sup>2</sup> = 0.19), if = 32%         -1         -0.5         0         0.5           Test for overall effect Z = 3.60 (7 <sup>2</sup> = 0.003)         Favours [Control]         Favours [Control]         Favours [Control]         Favours [Control]	Zhao et al 2012	2.46	0.82	30	1.99	0.67	30	9.6%	0.47 [0.09, 0.85]	I	
Heterogeneity: Chi <sup>#</sup> = 7.37, df = 5 (P = 0.19); P = 32% Test for overall effect: Z = 3.60 (P = 0.0003) Favours (Control) Favours (Chi C	Total (95% CI)			166			158	100.0%	0.22 [0.10, 0.33]	•	
Test for overall effect: Z = 3.60 (P = 0.0003) -1 -0.5 0 0.5 Favours [Control] Favours [Gin] C	Heterogeneity; ChiP =	7.37. df	= 5 (P	= 0.19	); <b> ²</b> = 32	1%					
	Test for overall effect:	Z = 3.60	) (P = (	0.0003)						-1 -0.5 0 0.5 Favours (Control) Favours (Gin)	

**Figure 4:** Forest plot of relevant immune globulin between glutamine and control group. (a) Change of concentration of IgG between glutamine and control group: Fixed-effects model. (b) Change of concentration of IgM between glutamine and control group: Fixed-effects model. (c) Change of concentration of IgA between glutamine and control group: Fixed-effects model.

		Gin		c	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV. Random, 95% Cl
Aosasa et al 1999	6.1	1.6	6	7.1	5.1	5	35.3%	-1.00 [-5.65, 3.65]	
Cui et al 2011	49	10	20	68	13	20	32.4%	-19.00 [-26.19, -11.81]	
Lu et al 2011	12.6	11.7	25	15.2	14.1	25	32.4%	-2.60 [-9.78, 4.58]	
Total (95% CI)			51			50	100.0%	-7.34 [-18.15, 3.47]	-
Heterogeneity: Tau <sup>2</sup> =	-20 -10 0 10 20								
lest for overall effect:	Z = 1.33	s (P = t	J.18)						Favours [Control] Favours [GIn]

**Figure 6:** Forest plot of change of concentration of tumor necrosis factor- $\alpha$ ; between glutamine and control group: Random-effects model.

the conclusion that Gln enriched nutrition support had no more difference in changing the incidence of noninfectious complications than standard nutrition [Figure 7b].

#### Length of hospital stay

Four studies<sup>[19,22,26,27]</sup> with 729 subjects mentioned the length of hospital stay.  $I^2$  between studies was 91% (P < 0.05; Chi-square = 32.53), thus a random-effects model was used. Analysis showed that nutrition support was more effective in shortening the length of hospital stay than control group (MD: -1.72; 95% CI: -3.31–-0.13; P < 0.05) [Figure 7c].

## DISCUSSION

Gastrointestinal cancer patients often accompanied by malnutrition and immune dysfunction, thereby slowing the recovery after surgical trauma and increasing mortality.<sup>[28,29]</sup> During surgical stress, the consumption of Gln exceeds the synthesis, resulting in depletion of Gln stores.<sup>[30]</sup> Moreover, the limited intestinal reserves and surgical fasting period would further aggravating relative lack of Gln. In that situation, supplement of Gln became necessary. Gln has various physiological functions in the body. Above all, the oxidation of Gln was the nitrogen source for other amino acids and protein, which in turn preventing muscle degradation and increasing protein synthesis.<sup>[31,32]</sup> In this meta-analysis, although the Gln enriched nutrition support had no significant effect on change of serum total protein,

		Gin			.onu oi			Mean Difference	mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	t IV, Fixed, 95% CI	IV, Fixed, 95% Cl
Wang et al 2007	51.3	3.15	30	47.5	2.14	30	69.6%	3.80 [2.44, 5.16]	
Xia et al 2006	69.16	4.83	20	64.42	11.66	20	4.2%	4.74 [-0.79, 10.27]	
Yang et al 2008	71.4	10.1	70	66.8	9.3	62	11.8%	4.60 [1.29, 7.91]	
Zhao et al 2012	52.57	5.67	30	50.32	6.15	30	14.4%	2.25 (-0.74, 5.24)	
Total (95% CI)			150			142	100.0%	3.71 [2.57, 4.85]	•
Heterogeneity: Chi <sup>2</sup> =	1.34 df	= 3 (P	= 0.72)	· F = 09	6				
Test for overall effect	7=640	N/P < I	100001	n	•				-4 -2 0 2 4 a
	2 0.10			·					Favours [Control] Favours [Gin]
		Chu		0	ontrol			Mean Difference	Maan Difforance
Study or Subgroup	Maan	su	Total	Mean	SD	Total	Moight	M Random 05% Cl	Mean Difference
Ween at al 2007	48.0	6.05	20	06.1.1	50	20	20.20	11.00 (0.01 10.07)	IV, Rahuolii, 95% Ci
Wang et al 2007	40.2	0.05	30	35.11	5.3	30	20.2%	0.07[7:65_40.00]	
Weng et al 2006	47.1	2.11	15	37.13	4.07	15	20.7%	9.97 [7.65, 12.29]	
xia et al 2006	41.03	7.08	20	47.25	7.92	20	18.2%	-0.22 [-10.88, -1.50]	
Yang et al 2008	39.1	3.6	70	36.81	3.32	62	21.5%	2.29 [1.11, 3.47]	
Zhao et al 2012	36.63	6.93	30	34.35	7.56	30	19.4%	2.28 [-1.39, 5.95]	
Tetel (OFF CB			405			457	400.00	4 447 0 00 0 004	
Total (95% CI)		0.1.17	105	~ . ~		157	100.0%	4.11[-0.82, 9.04]	
Heterogeneity: I au-=	29.10;1	unite i	10.09,0	JI = 4 (P	< 0.00	001); r	-= 95%		-10 -5 0 5 10 1
lest for overall effect:	Z = 1.64	(P=0	(10)						Favours [Control] Favours [GIn]
		Cin			ontrol			Maan Difference	Maga Difference
Church and Carbon and		oin co	T-4-1		onuoi	T	18/-1-1-1-1	Mean Difference	Mean Difference
Study of Subgroup	Mean	50	Total	Mean	50	10121	weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
weng et al 2006	20.83	2.54	15	19.89	2.63	15	10.0%	0.94 [-0.91, 2.79]	
Xia et al 2006	23.01	8.03	20	22.97	6.69	20	2.7%	0.04 [-4.54, 4.62]	
Yang et al 2008	20.8	2.92	70	21.3	2.28	62	72.0%	-0.50 [-1.39, 0.39]	
Zhao et al 2012	26.7	4.03	30	28.63	5.93	30	8.6%	-1.93 [-4.50, 0.64]	
Total (95% CI)			135			127	100.0%	-0.37 [-1.12, 0.38]	<b>T</b>
Heterogeneity: Chi <sup>2</sup> =	: 3.46, di	f= 3 (P	= 0.33	); <b>I<sup>2</sup> =</b> 13	3%				-10 -5 0 5 10
Test for overall effect:	Z = 0.9	6 (P = I	D.34)						Favours (Control) Favours (GIn)
									C
		Glu		0	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Moan	60	Total	Moan	SD	Total	Woight	M Pandom 05% Cl	Mean Direfence
Ware at al 2007	4.70	0.16	20	4 30	0.12	20	20.70	0.2510.20.0.421	IV, Randolli, 95% Ci
Wang et al 2007	2.45	0.15	30	1.30	0.13	30	40.000	0.35 [0.26, 0.42]	
Weng et al 2006	2.45	0.23	15	1.97	0.32	15	19.076	0.46 [0.26, 0.66]	
XIa et al 2006	2.37	1.03	20		0.84	20	5.4%	0.37 [-0.21, 0.95]	_
Yang et al 2008	1.9	0.43	70	1.7	0.38	62	24.3%	0.20 [0.06, 0.34]	
∠nao et al 2012	1.04	U.38	30	1.01	0.3	30	21.7%	0.03 (-0.14, 0.20)	
Tatal (OEK CD			405			457	400.00	0.071040.0401	
Total (95% CI)			165			157	100.0%	0.27 [0.12, 0.42]	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> =	0.02; C	hr≓ = 1	165 5.43, df	'= 4 (P :	= 0.002	157 ); I² = 7	100.0% 6%	0.27 [0.12, 0.42]	-1 -0.5 0 0.5
Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	0.02; C Z = 3.66	hi² = 1 ∂ (P = 0	165 5.43, df 1.0004)	= 4 (P =	= 0.002	157 ); I² = 7	100.0% 6%	0.27 [0.12, 0.42]	-1 -0.5 0 0.5 Favours [Control] Favours [Gin] d
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	0.02; C Z = 3.56	hi≇ = 1 i (P = 0	165 5.43, df 1.0004)	'= 4 (P :	= 0.002	157 ); I² = 7	100.0% 6%	0.27 [0.12, 0.42]	-1 -0.5 0 0.5 Favours [Control] Favours [Gin]

**Figure 5:** Forest plot of relevant immune indices between glutamine and control group. (a) Change of CD3<sup>+</sup> T-cell between glutamine and control group: Fixed-effects model. (b) Change of CD4<sup>+</sup> T-cell between glutamine and control group: Random-effects model. (c) Change of CD8<sup>+</sup> T-cell between glutamine and control group: Fixed-effects model. (d) Change of CD4/CD8 ratio between glutamine and control group: Random-effects model.

	Gin		Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Gianotti et al 2009	41	212	37	216	40.2%	1.13 [0.76, 1.69]	+
Huang et al 2002	0	11	2	11	2.7%	0.20 [0.01, 3.74]	
Lu et al 2011	0	25	4	25	4.9%	0.11 [0.01, 1.96]	← <u>−</u> +
Oguz et al 2007	5	57	14	52	16.1%	0.33 [0.13, 0.84]	
Weng et al 2006	0	15	2	15	2.7%	0.20 [0.01, 3.85]	
Xia et al 2006	1	20	2	20	2.2%	0.50 [0.05, 5.08]	
Yang et al 2008	11	70	21	62	24.5%	0.46 [0.24, 0.88]	
Zhao et al 2012	2	30	6	30	6.6%	0.33 [0.07, 1.52]	
							.
Total (95% CI)		440		431	100.0%	0.67 [0.50, 0.90]	◆
Total events	60		88				
Heterogeneity: Chi <sup>2</sup> =	13.61, df	= 7 (P =	= 0.06); f	² = 49%			
Test for overall effect:	Z = 2.67	(P = 0.0	)08)				Eavoure (Control) Eavours (Gin)
							Pavours (control) + avours (control of
	Gln		Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Gianotti et al 2009	33	212	34	216	77.3%	0.99 [0.64, 1.54]	
Huang et al 2002	0	11	1	11	3.4%	0.33 (0.02, 7.39)	
Oguz et al 2007	1	57	8	52	19.2%	0.11 [0.01, 0.88]	
-							
Total (95% CI)		280		279	100.0%	0.80 [0.53, 1.21]	•
Total events	34		43				1
Heterogeneity: Chi <sup>2</sup> =	4.70, df=	2 (P =	0.10); l <sup>e</sup> :	= 57%			
Test for overall effect:	Z = 1.07	(P = 0.2	28)				Envoure (Control) Envoure (Gin)
							Pavours (control) Pavours (control D
	Gin		60	etrol		Moon Difference	Mean Difference
Study or Subgroup	Mean Si	Total	- Mean	SD Tr	atal Wein	bit N/ Random 95%	CI IV. Random 95% CI
Gianotti et al 2009	10.2 41	2 212	/ 99	20 1	216 27 2	0% 0.30F0.53.1.1	21
Onuz et al 2007	6 1.3	57	8.3	1.1	52 28.6	-2.30 -2.731.8	71
Yang et al 2008	5 3	70	1 8	5	62 23.8	-3.00 -4.43, -1.5	71
Zhao et al 2012	11.2 3.	5 30	13.3	4.3	30 20.2	-2.10 -4.08, -0.1	21
Total (95% CI)		369	)	5	360 100.0	.1.72 [-3.31, -0.1	3]
Heterogeneity: Tau <sup>2</sup> = 2	.24; Chi <sup>2</sup> :	= 32.53,	df = 3 (P	< 0.000	001); l² = 9	1%	
Test for overall effect: Z	= 2.12 (P	= 0.03)					Eavours (Control) Eavours (Gin)

**Figure 7:** Forest plot of relevant clinical outcomes between glutamine and control group. (a) Change of infectious complications between glutamine and control group: Fixed-effects model. M-H: Mantel-Haenszel test. (b) Change of noninfectious complications between glutamine and control group: Fixed-effects model. M-H: Mantel-Haenszel test. (c) Change of length of hospital stay between glutamine and control group: Random-effects model.

levels of serum albumin, prealbumin and transferring were increased significantly, suggesting Gln enhanced nutritional support benefited protein synthesis for surgical patients with GI tumor. Furthermore, Gln is an indispensable material for the proliferation of immune cell. It is avidly consumed by rapidly dividing cells, such as immune cells, intestinal mucosal cells, fibroblasts and tumor cells.<sup>[33-35]</sup> The high efficiency of Gln in many immune cells has a strong association with the functional activity of these cells, such as cell proliferation, antigen presentation, cytokine synthesis, nitric oxide and superoxide production and phagocytosis.<sup>[36,37]</sup> Our anylysis showed that Gln could increase the postoperative concentration of CD3<sup>+</sup> T-cell and raised CD4/CD8 ratio of patients, suggesting that Gln could promote the proliferation of lymphocytes to some extent, thus enhancing body's cellular immune function.

Additionally, as the main energy source of the intestinal tract, Gln is the most important nutrient for intestinal repair, preventing mucosal atrophy process via PN.<sup>[38]</sup> Due to the complexity of intestinal immune system, many cells are involved in the immune function of gut, such as macrophages, natural killer cells and lymphocytes, of which the salivary IgA (S-IgA) secreted by plasmocyte could effectively prevent bacterial adhesion to the intestinal mucosa.<sup>[39,40]</sup> Study found that Gln can promote the secretion of intestinal S-IgA that further increase coated rate of bacteria, reduce bacterial adhesion, improve the quantity of CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup> lymphocytes, and then prevent bacterial translocation.<sup>[41]</sup> Moreover, bacterial translocation is closely related to a decrease of adenosine triphosphate level in intestinal epithelial cells. However, as an acute depletion of Gln, the bacterial translocation induced by cytokine is a process across the cell rather than through the cell gap.<sup>[42,43]</sup> Therefore, Gln plays a critical role in the protection of the intestinal immune barrier and the resistance of microbe, as the energy substrate of intestinal epithelial cells. In this meta-analysis, patients in Gln group had a significant higher concentration of IgG, IgM and IgA, lower incidence of infectious complications and shorter length of hospital stay. Gln could improve the body's immune globulin, and reduce the inflammatory response and the risk of postoperative infection, thus promote postoperative recovery.

Tumor necrosis factor alpha, being an endogenous pyrogen, is able to induce fever, apoptotic cell death, cachexia, inflammation and to inhibit tumorigenesis and viral replication.<sup>[44,45]</sup> Dysregulation of TNF- $\alpha$  production has been implicated in a variety of human diseases including Alzheimer's disease,<sup>[46]</sup> cancer<sup>[47]</sup> and inflammatory bowel disease.<sup>[48]</sup> Moreover, the concentrations of serum TNF- $\alpha$ has been postulated as a biochemical marker of tissue injury, which is a major reactive mediator during inflammation.<sup>[49]</sup> TNF- $\alpha$  is also a proinflammatory cytokine, despite it not being reduced significantly in our meta-analysis. As shown in the study of Yaqoob and Calder,<sup>[50]</sup> Gln had a smaller effect on T-cell-drived TNF- $\alpha$  generation.

This meta-analysis systematically reviewed the effects of Gln enriched nutrition support on surgical patients with GI tumor from the aspects of relevant biochemical indices, immune indices and clinical outcomes. However, it also exists some limitations. Firstly, a large proportion of included studies came from China, literatures of other areas were relatively few, which may brought selection bias. Secondly, the thirteen included trials all mentioned randomization and parallel control, but did not about blind, which making some trials' study-quality score lower relatively. Thirdly, the study-quality score of Gianotti *et al.*<sup>[19]</sup> was three but the number of enrolled subjects was large, which will bring uncertainty biases to the final result of the meta-analysis. Fourthly, statistically significant results were not equal to the effective clinical significance, which provided clinical evidence for the effectiveness and the rational application of Gln to clinicians. Overall, more large-sample and multicenter RCTs are still needed to verification in the future.

Glutamine enriched nutrition support was superior in improving immune function, reducing the incidence of infectious complications and shortening the length of hospital stay, playing an important role in the rehabilitation of surgical GI cancer patients.

# REFERENCES

- Hawkins RA, O'Kane RL, Simpson IA, Viña JR. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 2006;136 1 Suppl:218S-26.
- Kao C, Hsu J, Bandi V, Jahoor F. Alterations in glutamine metabolism and its conversion to citrulline in sepsis. Am J Physiol Endocrinol Metab 2013;304:E1359-64.
- Tanhoffer RA, Yamazaki RK, Nunes EA, Pchevozniki AI, Pchevozniki AM, Nogata C, *et al.* Glutamine concentration and immune response of spinal cord-injured rats. J Spinal Cord Med 2007;30:140-6.
- Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007;178:93-105.
- Salomão EM, Gomes-Marcondes MC. Light aerobic physical exercise in combination with leucine and/or glutamine-rich diet can improve the body composition and muscle protein metabolism in young tumor-bearing rats. J Physiol Biochem 2012;68:493-501.
- 6. Austgen TR, Dudrick PS, Sitren H, Bland KI, Copeland E, Souba WW. The effects of glutamine-enriched total parenteral nutrition on tumor growth and host tissues. Ann Surg 1992;215:107-13.
- Kew S, Wells SM, Yaqoob P, Wallace FA, Miles EA, Calder PC. Dietary glutamine enhances murine T-lymphocyte responsiveness. J Nutr 1999;129:1524-31.
- Yoshida S, Kaibara A, Ishibashi N, Shirouzu K. Glutamine supplementation in cancer patients. Nutrition 2001;17:766-8.
- Eagle H, Piez K. The population-dependent requirement by cultured mammalian cells for metabolites which they can synthesize. J Exp Med 1962;116:29-43.
- Wasa M, Bode BP, Abcouwer SF, Collins CL, Tanabe KK, Souba WW. Glutamine as a regulator of DNA and protein biosynthesis in human solid tumor cell lines. Ann Surg 1996;224:189-97.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
- Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006;59:7-10.
- Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: An updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:1189-96.
- Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101-5.

- Aosasa S, Mochizuki H, Yamamoto T, Ono S, Ichikura T. A clinical study of the effectiveness of oral glutamine supplementation during total parenteral nutrition: Influence on mesenteric mononuclear cells. JPEN J Parenter Enteral Nutr 1999;23:S41-4.
- Cui Y, Hu L, Liu YJ, Wu YM, Jing L. Effect of N(2)-L-alanyl-L-glutamine on perioperative insulin resistance in patients undergoing colon cancer resection (in Chinese). Chin J Anesthesiol 2011;31:785-8.
- Dai YX, Yue QJ, Shi YS, Xue PH. Effect of glutamine-intensified total parenteral nutrition on the postoperative patients with gastrointestinal tract tumour (in Chinese). Clin J Surg 2001;9:92-3.
- Erdem NZ, Yasti AC, Atli M, Gozalan AU, Dolapci M, Kama NA, et al. The effects of perioperative oral enteral support with glutamine-added elemental formulas in patients with gastrointestinal cancers: A prospective, randomized, clinical study. Nutr Res 2002;22:977-88.
- Gianotti L, Braga M, Biffi R, Bozzetti F, Mariani L. GlutamItaly Research Group of the Italian Society of Parenteral, and Enteral Nutrition. Perioperative intravenous glutamine supplemetation in major abdominal surgery for cancer: A randomized multicenter trial. Ann Surg 2009;250:684-90.
- Huang MS, Zhuang YZ, Liu DJ, Huang WH, Wang WF, Chen SF. Effect of glutamine-enriched parenteral nutrition on one-stage resection of colorectal carcinoma with acute obstruction (in Chinese). Chin J Clin Nutr 2002;10:195-7.
- Lu CY, Shih YL, Sun LC, Chuang JF, Ma CJ, Chen FM, *et al.* The inflammatory modulation effect of glutamine-enriched total parenteral nutrition in postoperative gastrointestinal cancer patients. Am Surg 2011;77:59-64.
- Oguz M, Kerem M, Bedirli A, Mentes BB, Sakrak O, Salman B, et al. L-alanin-L-glutamine supplementation improves the outcome after colorectal surgery for cancer. Colorectal Dis 2007;9:515-20.
- Wang SF, Che XM. Effect of postoperative immunonutrition on gastrointestinal cancer (in Chinese). Chin J Gen Surg 2007;16:912-4.
- Weng ZY, Fei ZW, Wu KJ, Yang Y, Zhang YC. Influence of different enteral nutritional support regimens on the nutritional status of post-operative patients with gastric cancer (in Chinese). J Surg Concepts Pract 2006;11:227-30.
- 25. Xia Q, Chen P, Liu J, Zhong FQ. Effects of perioperative glutamine-supplemented total parenteral nutrition support on immune function of patients with gastro intestinal cancer (in Chinese). Parenter Enteral Nutr 2006;13:148-51.
- 26. Yang Y, Li Q, Wang HZ, Ren H, Yang NZ. Effects of postoperative early glutamine supplemented enteral nutrition on the treatment of critically ill patients after the digestive tract cancer radical operation (in Chinese). Chin J Anesthesiol 2008;24:244-6.
- 27. Zhao Y, Zhang CC, Zheng GL, Zhang T, Zhang JJ, Zhu HT, et al. Alanyl-glutamine supplementation in total parenteral nutrition in gastric cancer operation patients of nutritional risk: The clinical significance on immune system, nutritional status and postoperative recovery. Prog Mod Biomed 2012;12:3693-7.
- Al Balushi RM, Cohen J, Banks M, Paratz JD. The clinical role of glutamine supplementation in patients with multiple trauma: A narrative review. Anaesth Intensive Care 2013;41:24-34.
- 29. Stachowicz-Stencel T, Synakiewicz A. Glutamine as a supplemental treatment in pediatric and adult oncology patients. Expert Opin Investig Drugs 2012;21:1861-71.
- Cynober L, De Bandt JP. Glutamine in the intensive care unit. Curr Opin Clin Nutr Metab Care 2014;17:98-104.
- Coster J, McCauley R, Hall J. Glutamine: Metabolism and application in nutrition support. Asia Pac J Clin Nutr 2004;13:25-31.
- Chamney C, Godar M, Garrigan E, Huey KA. Effects of glutamine supplementation on muscle function and stress responses in a mouse model of spinal cord injury. Exp Physiol 2013;98:796-806.

- 33. Han T, Li XL, Cai DL, Zhong Y, Geng SS. Effects of glutamine-supplemented enteral or parenteral nutrition on apoptosis of intestinal mucosal cells in rats with severe acute pancreatitis. Eur Rev Med Pharmacol Sci 2013;17:1529-35.
- Chambers JW, Maguire TG, Alwine JC. Glutamine metabolism is essential for human cytomegalovirus infection. J Virol 2010;84:1867-73.
- 35. Oliveira GP, Dias CM, Pelosi P, Rocco PR. Understanding the mechanisms of glutamine action in critically ill patients. An Acad Bras Cienc 2010;82:417-30.
- Bell SG. Immunomodulation. Part IV: Glutamine. Neonatal Netw 2006;25:439-43.
- Hammami I, Chen J, Bronte V, DeCrescenzo G, Jolicoeur M. L-glutamine is a key parameter in the immunosuppression phenomenon. Biochem Biophys Res Commun 2012;425:724-9.
- Owari M, Wasa M, Oue T, Nose S, Fukuzawa M. Glutamine prevents intestinal mucosal injury induced by cyclophosphamide in rats. Pediatr Surg Int 2012;28:299-303.
- Pérez-Bárcena J, Crespí C, Regueiro V, Marsé P, Raurich JM, Ibáñez J, *et al.* Lack of effect of glutamine administration to boost the innate immune system response in trauma patients in the intensive care unit. Crit Care 2010;14:R233.
- 40. Zhou Y, Zhang P, Deng G, Liu X, Lu D. Improvements of immune status, intestinal integrity and gain performance in the early-weaned calves parenterally supplemented with L-alanyl-L-glutamine dipeptide. Vet Immunol Immunopathol 2012;145:134-42.
- Alverdy JA, Aoys E, Weiss-Carrington P, Burke DA. The effect of glutamine-enriched TPN on gut immune cellularity. J Surg Res 1992;52:34-8.
- 42. Karatepe O, Acet E, Battal M, Adas G, Kemik A, Altiok M, et al. Effects of glutamine and curcumin on bacterial translocation in jaundiced rats. World J Gastroenterol 2010;16:4313-20.
- 43. Sözen S, Topuz O, Uzun AS, Cetinkünar S, Das K. Prevention of bacterial translocation using glutamine and melatonin in small bowel ischemia and reperfusion in rats. Ann Ital Chir 2012;83:143-8.
- 44. Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 2007;18:335-43.
- Juhász K, Buzás K, Duda E. Importance of reverse signaling of the TNF superfamily in immune regulation. Expert Rev Clin Immunol 2013;9:335-48.
- 46. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010;68:930-41.
- 47. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001;104:487-501.
- 48. Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, *et al.* Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43.
- Kinra P, Dutta V. Serum TNF alpha levels: A prognostic marker for assessment of severity of malaria. Trop Biomed 2013;30:645-53.
- Yaqoob P, Calder PC. Cytokine production by human peripheral blood mononuclear cells: Differential sensitivity to glutamine availability. Cytokine 1998;10:790-4.

Received: 21-08-2014 Edited by: Li-min Chen How to cite this article: Kang K, Shu XL, Zhang YS, Liu XL, Zhao J. Effect of Glutamine Enriched Nutrition Support on Surgical Patients with Gastrointestinal Tumor: A Meta-Analysis of Randomized Controlled Trials. Chin Med J 2015;128:245-51.

Source of Support: Nil. Conflict of Interest: None declared.